Compare Vertex Pharmaceuticals Incorporated (VRTX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs 22nd Century Group Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 205173.2× 22nd Century Group Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and 22nd Century Group Inc for 32 Days on average.
| VRTX | XXII | |
|---|---|---|
Market Cap | $127.55B | $621.67K |
Volume | 1,487,944 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $557.96 | $483.00 |
52-Week Low | $407.37 | $0.80 |
Typical Hold Time | 120 Days | 32 Days |
Enterprise Value | $121.68B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
